DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Prevnar (Pneumococcal 7-Valent Conjugate Vaccine (Diphtheria CRM 197 Protein)) - Summary

 


Nutrilib.com
A comprihensive source of nutritional information

PREVNAR SUMMARY

Pneumococcal 7-valent Conjugate Vaccine (Diphtheria CRM197 Protein), Prevnar® , is a sterile solution of saccharides of the capsular antigens of Streptococcus pneumoniae serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F individually conjugated to diphtheria CRM197 protein. Each serotype is grown in soy peptone broth. The individual polysaccharides are purified through centrifugation, precipitation, ultrafiltration, and column chromatography.

Prevnar® is indicated for active immunization of infants and toddlers against invasive disease caused by S. pneumoniae due to capsular serotypes included in the vaccine (4, 6B, 9V, 14, 18C, 19F, and 23F). The routine schedule is 2, 4, 6, and 12-15 months of age.

The decision to administer Pneumococcal 7-valent Conjugate Vaccine (Diphtheria CRM197 Protein), Prevnar® should be based primarily on its efficacy in preventing invasive pneumococcal disease. As with any vaccine, Prevnar® may not protect all individuals receiving the vaccine from invasive pneumococcal disease.

Prevnar® is also indicated for active immunization of infants and toddlers against otitis media caused by serotypes included in the vaccine. However, for vaccine serotypes, protection against otitis media is expected to be substantially lower than protection against invasive disease. Additionally, because otitis media is caused by many organisms other than serotypes of S. pneumoniae represented in the vaccine, protection against all causes of otitis media is expected to be low.


See all Prevnar indications & dosage >>

PREVNAR NEWS HIGHLIGHTS

Media Articles Related to Prevnar (Pneumococcal Vaccine)

Adult Smokers Need Pneumococcal Vaccine
Source: MedicineNet Pneumococcal Vaccination Specialty [2008.10.23]

more >>

Published Studies Related to Prevnar (Pneumococcal Vaccine)

Initial and subsequent response to pneumococcal polysaccharide and protein-conjugate vaccines administered sequentially to adults who have recovered from pneumococcal pneumonia. [2008.10.01]

Safety and immunogenicity of a 7-valent pneumococcal conjugate vaccine (Prevenar): primary dosing series in healthy Chinese infants. [2008.04.24]

Randomized, controlled trial efficacy of pneumococcal conjugate vaccine against otitis media among navajo and white mountain apache infants. [2008.01]

A randomized, double-blind trial of pneumococcal vaccination in adult allogeneic stem cell transplant donors and recipients. [2007.12.15]

A novel combined Haemophilus influenzae type b-Neisseria meningitidis serogroups C and Y-tetanus-toxoid conjugate vaccine is immunogenic and induces immune memory when co-administered with DTPa-HBV-IPV and conjugate pneumococcal vaccines in infants. [2007.12.12]

more >>

Clinical Trials Related to Prevnar (Pneumococcal Vaccine)

Immuno-Augmentation With GM-CSF of Pneumococcal Vaccine in Chronic Lymphocytic Leukemia Patients [Active, not recruiting]

Pneumococcal Conjugate Vaccine With Pneumococcal Polysaccharide Vaccine and Tetanus/Diphtheria Vaccine [Active, not recruiting]

Vancomycin Concentration in Cerebrospinal Fluid During Pneumococcal Meningitis [Completed]

Comparison of a DTaP-IPV-HB-PRP~T Combined Vaccine to Infanrix™-Hexa, When Administered With Prevnar® in Thai Infants [Active, not recruiting]

Antibody Responses to Pneumococcal Vaccines Among HIV-Infected Adults. [Completed]

more >>

Page last updated: 2008-11-02

-- advertisement -- The American Red Cross

We comply with
HONcode standard.
Verify here.
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2008